Results 31 to 40 of about 35,256 (161)

Ocrelizumab-Induced Severe Colitis

Case Reports in Gastrointestinal Medicine, 2020
We report a case of severe ocrelizumab (anti-CD20 monoclonal antibody) induced colitis in a 43-year-old woman with multiple sclerosis leading to total colectomy after failing medical therapy.
Hsing Hwa Lee, Naveen Sritharan, Daniel Bermingham, Gabriela Strey   +3 more
doaj   +1 more source

Maintained partial protection against Streptococcus pneumoniae despite B‐cell depletion in mice vaccinated with a pneumococcal glycoconjugate vaccine

Clinical & Translational Immunology, 2022
Objectives Anti‐CD20 monoclonal antibody therapy rapidly depletes > 95% of CD20+ B cells from the circulation. B‐cell depletion is an effective treatment for autoimmune disease and B‐cell malignancies but also increases the risk of respiratory tract ...
Giuseppe Ercoli, Elisa Ramos‐Sevillano, Emma Pearce, Sara Ragab, David Goldblatt, Gisbert Weckbecker, Jeremy S Brown   +6 more
doaj   +1 more source

Research advances of obinutuzumab in the treatment of membranous nephropathy

Linchuang shenzangbing zazhi
Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN.
Xiao-jing Lin, Jing Sun, Hao-yi Xiangli, Xuan-yi Du   +3 more
doaj   +1 more source

Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131

Brazilian Archives of Biology and Technology, 2005
Radioactive isotopes of iodine, mainly iodine-131 have been broadly used in many monoclonal antibody radioiodination settings, employing different methods.
Akinkunmi Ganiyu Akanji, Emiko Muramoto, José de Souza Caldeira Filho, Renata Martinussi Couto, Elaine Bortoletti de Araújo   +4 more
doaj   +1 more source

Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab

Case Reports in Neurology
Introduction: Ocrelizumab is a recombinant humanized anti-CD20 monoclonal antibody used to treat multiple sclerosis. Late-onset neutropenia, absolute neutrophil count <1.5 × 109/L that develops >4 weeks after last drug administration, is
Casey J. Fealko, Morgan N. Rolon-Newton, Marisa J.L. Aitken, Scott D. Gitlin   +3 more
doaj   +1 more source

BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. [PDF]

PLoS ONE, 2013
AIMS: Option to attenuate atherosclerosis by depleting B2 cells is currently limited to anti-CD20 antibodies which deplete all B-cell subtypes. In the present study we evaluated the capacity of a monoclonal antibody to B cell activating factor-receptor ...
Tin Kyaw, Peng Cui, Christopher Tay, Peter Kanellakis, Hamid Hosseini, Edgar Liu, Antonius G Rolink, Peter Tipping, Alex Bobik, Ban-Hock Toh   +9 more
doaj   +1 more source

New anti-CD20 monoclonal antibodies: which is the best? [PDF]

Leukemia & Lymphoma, 2014
Rituximab (MabTh era â , Rituxan â ), a chimeric immunoglobulin G1 (IgG1) monoclonal antibody (Mab) targeting CD20, has dramatically improved the outcome of most B-cell lymphoproliferative disorders. Regarding the clinical effi cacy of this Mab, little is known however on how rituximab works in vivo , and it is speculated that rituximab induces both Fv-
Anne-Laure, Gagez, Guillaume, Cartron
openaire   +2 more sources

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

International Journal of Nanomedicine, 2016
Shuang Jiang,1,2,* Xiaobo Wang,2,* Zhiran Zhang,2 Lan Sun,3 Yunzhu Pu,3 Hongjuan Yao,3 Jingcao Li,3 Yan Liu,3 Yingge Zhang,3 Weijing Zhang1,4 1Department of Lymphoma, Affiliated Hospital of the Military Medical Academy of Sciences, Beijing, 2Department ...
Jiang S, Wang X, Zhang Z, Sun L, Pu Y, Yao H, Li J, Liu Y, Zhang Y, Zhang W   +9 more
doaj  

Combination of anti-CD20 and hetrombopag in relapsed/refractory immune thrombocytopenia: a case series

Frontiers in Medicine
PurposeThis study aimed to assess the effectiveness of anti-CD20 monoclonal antibody and hetrombopag for relapsed/refractory immune thrombocytopenia (ITP) following glucocorticoid treatment.MethodsWe retrospectively included four patients with relapsed ...
Xiaolei Zhang, Yang Li, Yujie Guo, Xuquan Zhou, Fengru Lin, Yan Wang, Lina Xing   +6 more
doaj   +1 more source

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Pharmacogenomics and Personalized Medicine, 2014
Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj